Targeting STAT3 in Heme Cancers: The Emergence of KYM-003 as a Novel Therapeutic Degrader

3 June 2024
The research introduces KYM-003, a new agent designed to target and degrade STAT3, a transcription factor implicated in various cancers. This compound leverages the cellular ubiquitin proteasome system to degrade STAT3, which has been associated with cancer cell survival and immune evasion. The study details the development and evaluation of KYM-003, highlighting its effectiveness in vitro and in vivo, particularly in models dependent on STAT3 activity.

The methodology involved several assays to assess the binding and degradation capabilities of KYM-003. These included fluorescence polarization to characterize binary binding, AlphaLISA to measure ternary complex formation, and immunoassays to quantify STAT3 levels and ubiquitination in human cell lysates. The impact on STAT3 signaling was monitored through gene expression levels using RT-qPCR, and cell viability was assessed using the CellTiter-Glo assay. Tumor xenograft studies were conducted in immune-compromised mice to evaluate the compound's antitumor activity.

Key findings indicate that KYM-003 induces STAT3 degradation through an E3 ligase-dependent pathway, showing strong binding and cooperativity in complex formation. It induced endogenous STAT3 ubiquitination and robustly degraded STAT3 in various cells with high selectivity, affecting no other STAT family members. The compound led to significant downregulation of STAT3 target genes and substantially reduced STAT3 levels in tumors, demonstrating sustained antitumor effects with repeated dosing.

The study concludes that KYM-003 is a potent and selective degrader of STAT3, exhibiting strong antitumor activity in heme cancer models, and suggests that STAT3 degraders could be a promising therapeutic approach.

The citation for this research is: Fred Csibi et al., "Discovery of KYM-003, a potent and selective STAT3 degrader with antitumor activity in heme malignancies," in Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, 2019.

How to Use Synapse Database to Search and Analyze Translational Medicine Data?

The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.

图片包含 应用程序

描述已自动生成

Click on the image below to go directly to the Translational Medicine search interface.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成